Loading
Histone deacetylases tighten the packaging of DNA so that genes are switched off. Drugs that block them loosen the packaging and can wake up genes that make lymphoma cells stop growing or die. This dossier gathers the 3 products (1 approved), 5 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Inhibition causes histone hyperacetylation, cell-cycle arrest via p21 induction, apoptosis and reduced angiogenesis; class-related toxicities are fatigue, thrombocytopenia, diarrhoea and QT prolongation.
| Modality | Approved | Phase 2 | Withdrawn or failed |
|---|---|---|---|
| Small molecule 3 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
MAVORIC NCT01728805 | 3 | Positive | Previously treated mycosis fungoides or Sezary syndrome: the anti-CCR4 antibody mogamulizumab against the oral HDAC inhibitor vorinostat, with crossover allowed | Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018. | |
| 2 | Completed | A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment | - | ||
| 2 | Completed | A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma | - | ||
| 2 | Completed | A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study | - | ||
| 1/2 | Recruiting | An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC) | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Histone deacetylases" OR ABSTRACT:"Histone deacetylases" OR TITLE:"HDAC" OR ABSTRACT:"HDAC" OR TITLE:"HDAC1" OR ABSTRACT:"HDAC1" OR TITLE:"HDAC2" OR ABSTRACT:"HDAC2" OR TITLE:"HDAC3" OR ABSTRACT:"HDAC3" OR TITLE:"HDAC6" OR ABSTRACT:"HDAC6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Histone deacetylases (HDAC), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/hdac.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/hdac.json. Licence CC BY-NC 4.0.